InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Issues Update on Underwritten Public Offering of American Depositary Shares

AnPac Bio (NASDAQ: ANPC) today issued a correction to its press release dated Nov. 9, 2021, regarding the pricing of its underwritten public offering of American Depositary Shares (“ADSs”). According to the update, the original release referenced the dollar size of the offering and the number of ADSs being sold to include the exercise of the over-allotment option rather than just the base offering. The expected closing date has been updated to Nov. 15, 2021, for the offering of 1,132,111 ADSs, each at a public offering price of $2.22, for approximately $2.5 million in gross proceeds to the company. In connection with the offering, the company granted to the underwriter the option to purchase up to an additional 169,817 shares at the public offering price with the option exercisable within 45 days of the closing of the offering. EF Hutton, division of Benchmark Investments LLC, is acting as the sole book-running manager for the offering. To view the full press release, visit https://ibn.fm/jd0xD About AnPac Bio-Medical Science Co. Ltd. AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. For more information about the company, visit www.AnpacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW) 8033 Sunset Blvd Suite 1037-IW Los Angeles, CA 90046 310.299.1717 Office www.InvestorWire.com [email protected]

InvestorWire is part of the InvestorBrandNetwork.